Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: Results of a randomized, double-blind clinical study

Canadian Respiratory Journal

Volumn 9, Issue 2, 2002, Pages 107-115

  Kottakis, John ^a   Della Cioppa, Giovanni ^a   Creemers, Jacques ^a   Greefhorst, Louis ^a   Leclerc, Violette ^a   Pistelli, Riccardo ^a   Overend, Tim ^a   Till, Denise ^a   Rapatz, Günter ^a   Le Gros, Vincent ^a   Bouros, Demosthenes ^a   Siafakas, Nikolaos ^a  

^a NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

Beta2 agonists; Bronchodilators; Chronic obstructive pulmonary disease; Clinical trial; COPD; Formoterol; Salmeterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FORADIL AEROLIZER; FORMOTEROL FUMARATE; PLACEBO; SALBUTAMOL; SALMETEROL XINAFOATE; SEREVENT DISKUS; THEOPHYLLINE;

ADULT; AEROSOL; AGED; AREA UNDER THE CURVE; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; FEMALE; FORCED EXPIRATORY VOLUME; FRANCE; GREECE; HUMAN; ITALY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; NETHERLANDS; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STAGING;

EID: 0036303552     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2002/604092     Document Type: Article

References (30)

1. Time-course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic
2. Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma
3. Salmeterol versus formoterol in patients with moderately severe asthma: Onset and duration of action
4. Bronchodilator effect of inhaled formoterol vs salbutamol over 12 hours
5. Rapid onset of action of inhaled formoterol in asthmatic patients
6. Onset of bronchodilation and finger tremor induced by salmeterol and salbutamol in asthmatic patients
7. Salmeterol xinofoate: A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease
8. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease
9. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease
10. Onset of action of inhaled formoterol compared to ipratropium bromide in patients with COPD
11. Comparison of the efficacy, tolerability and safety of formoterol dry powder and oral slow-release theophylline in the treatment of COPD
12. Efficacy of salmeterol xinofoate in the treatment of COPD
13. Salmeterol reduces dyspnea and improves lung function in patients with COPD
14. 2-agonists for chronic obstructive pulmonary disease
15. Formoterol: Pharmacology, molecular basis of agonism, and mechanism of long duration of a potent and selective beta-2-andrenoceptor agonist bronchodilator
16. ERS consensus statement: Optimal assessment and management of chronic obstructive pulmonary disease (COPD)
17. BTS guidelines for the management of chronic obstructive pulmonary disease
18. Reproducibility of visual analog scale measurements of dyspnea in patients with chronic obstructive pulmonary disease
19. Effect of continuous positive airway pressure on respiratory sensation in patients with chronic obstructive pulmonary disease during submaximal exercise
20. Formoterol: An update of its pharmacological properties and therapeutic efficacy in the management of asthma
21. Lung volumes and forced ventilatory flows. Official statement of the European Respiratory Society
22. Formoterol improves the exercise performance in patients with chronic obstructive pulmonary disease
23. Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease
24. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive lung disease
25. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease
26. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action
27. Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD
28. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease
29. Rapid onset of bronchodilation in COPD: A placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk)
30. 2-agonists in the management of stable chronic obstructive pulmonary disease